AFAP1 and metabolic syndrome: Human randomized trials have provided evidence that FMT, transferring fecal material from healthy donors to patients with metabolic syndrome, leads to increased levels of SCFA-producing bacteria, notable changes in plasma metabolites involved in lipid metabolism, and reduced methylation levels of the actin-filament-associated protein 1 (AFAP1) promoter [135].